Manufacturing Industry
US pharma major Pfizer has been granted a worldwide licence for a cancer vaccine candidate CDX-110, which is currently in Phase II development for the treatment of glioblastoma multiforme, by Celldex Therapeutics, which in Q1 2008 became a subsidiary of US vaccine developer Avant Immunotherapeutics
Chemistry and Industry, June 9, 2008
US pharma major Pfizer has been granted a worldwide licence for a cancer vaccine candidate CDX-110, which is currently in Phase II development for the treatment of glioblastoma multiforme, by Celldex Therapeutics, which in Q1 2008 became a subsidiary of US vaccine developer Avant Immunotherapeutics.
CDX-110, which targets the tumour-specific molecule EGFRvlII, has been granted Fast Track and Orphan Drug status by the US Food & Drug Administration. The licence gives Pfizer the right to use EGFRvlII vaccines in other potential indications.
COPYRIGHT 2008 Society of Chemical Industry
COPYRIGHT 2008 Gale, Cengage Learning
Most Recent Technology Articles
- INTERVIEW WITH BEN BUTTERS, DIRECTOR OF EUROPEAN AFFAIRS AT EUROCHAMBRES : "A PERFECT ROAD MAP FOR EU CLUSTERS DOES NOT EXIST".
- AGENDA.(Brief article)(Conference notes)
- FIGHT AGAINST INTERNET PIRACY.
- INTERNET : AUTHORS' SOCIETIES URGE ACTION AGAINST PIRACY.
- TELECOMMUNICATIONS : BUSINESSEUROPE HOSTILE TO FURTHER CONTRACTUAL OBLIGATIONS.(Brief article)
Most Recent Technology Publications
Most Popular Technology Articles
- 3G: naughty or nice? PhoneErotica.com generates over 300 million hits per month, and rings up more minutes of use per month than MSN
- Business process re-engineering in the small firm: A case study
- Performance analysis of shell and tube heat exchanger using miscible system
- What is precision air conditioning and why is it necessary?
- Optimizing of Trichoderma viride cultivation in submerged state fermentation
Most Popular Technology Publications
Content provided in partnership with
